Although considered an organism of low virulence, Pneumocystis jiroveci is an important cause of pneumonia in immunocompromised hosts, especially those with hematologic malignancies, organ transplants, HIV infection, certain congenital immunodeficiencies, and those receiving potent immunosuppressive drugs [1–8]. As the population of immunosuppressed patients has grown, and as our ability to detect organisms in respiratory specimens has improved, more and more cases have been recognized in the period 1970–2000 [1–3]. Pneumocystis infections continue to cause morbidity and mortality among susceptible patients who do not receive chemoprophylaxis.


Immune Reconstitution Inflammatory Syndrome Severe Combine Immunodeficiency Disease Stem Cell Transplant Recipient Potent Immunosuppressive Drug Aerosolized Pentamidine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30 Suppl 1:S5–14.PubMedGoogle Scholar
  2. 2.
    Thomas Jr CF, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350:2487–98.PubMedGoogle Scholar
  3. 3.
    Brooks JT, Kaplan JE, Holmes KK, Benson C, Pau A, Masur H. HIV-associated opportunistic infections–going, going, but not gone: the continued need for prevention and treatment guidelines. Clin Infect Dis. 2009;48:609–11.PubMedGoogle Scholar
  4. 4.
    Cailliez JC, Seguy N, Denis CM, et al. Pneumocystis carinii: an atypical fungal micro-organism. J Med Vet Mycol. 1996;34:227–39.PubMedGoogle Scholar
  5. 5.
    Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature. 1988;334:519–22.PubMedGoogle Scholar
  6. 6.
    Stringer SL, Hudson K, Blase MA, Walzer PD, Cushion MT, Stringer JR. Sequence from ribosomal RNA of Pneumocystis carinii compared to those of four fungi suggests an ascomycetous affinity. J Protozool. 1989;36:14S–6S.PubMedGoogle Scholar
  7. 7.
    Barton E, Campbell WGJ. Pneumocystis carinii in lungs of rats treated with cortisone acetate: Ultrastructural observations relating to the life cycle. Am J Pathol. 1969;54:209–36.PubMedGoogle Scholar
  8. 8.
    Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1977;297:1419–26.PubMedGoogle Scholar
  9. 9.
    Edman JC, Edman U, Cao M, Lundgren B, Kovacs JA, Santi DV. Isolation and expression of the Pneumocystis carinii dihydrofolate reductase gene. Proc Natl Acad Sci USA. 1989;86:8625–9.PubMedGoogle Scholar
  10. 10.
    Volpe F, Ballantine SP, Delves CJ. The multifunctional folic acid synthesis fas gene of Pneumocystis carinii encodes dihydroneopterin aldolase, hydroxymethyldihydropterin pyrophosphokinase and dihydropteroate synthase. Eur J Biochem. 1993;216:449–58.PubMedGoogle Scholar
  11. 11.
    Basselin M, Hunt SM, Abdala-Valencia H, Kaneshiro ES. Ubiquinone synthesis in mitochondrial and microsomal subcellular fractions of Pneumocystis spp.: differential sensitivities to atovaquone. Eukaryot Cell. 2005;4:1483–92.PubMedGoogle Scholar
  12. 12.
    Huang L, Crothers K, Atzori C, et al. Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance. Emerg Infect Dis. 2004;10:1721–8.PubMedGoogle Scholar
  13. 13.
    Iliades P, Meshnick SR, Macreadie IG. Mutations in the Pneumocystis jiroveci DHPS gene confer cross-resistance to sulfa drugs. Antimicrob Agents Chemother. 2005;49:741–8.PubMedGoogle Scholar
  14. 14.
    Kessl JJ, Hill P, Lange BB, Meshnick SR, Meunier B, Trumpower BL. Molecular basis for atovaquone resistance in Pneumocystis jiroveci modeled in the cytochrome bc(1) complex of Saccharomyces cerevisiae. J Biol Chem. 2004;279:2817–24.PubMedGoogle Scholar
  15. 15.
    Nahimana A, Rabodonirina M, Bille J, Francioli P, Hauser PM. Mutations of Pneumocystis jiroveci dihydrofolate reductase associated with failure of prophylaxis. Antimicrob Agents Chemother. 2004;48:4301–5.PubMedGoogle Scholar
  16. 16.
    Stein CR, Poole C, Kazanjian P, Meshnick SR. Sulfa use, dihydropteroate synthase mutations, and Pneumocystis jiroveci pneumonia. Emerg Infect Dis. 2004;10:1760–5.PubMedGoogle Scholar
  17. 17.
    Gigliotti F. Pneumocystis carinii: has the name really been changed? Clin Infect Dis. 2005;41:1752–5.PubMedGoogle Scholar
  18. 18.
    Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis. 2002;8:891–6.PubMedGoogle Scholar
  19. 19.
    Kovacs JA, Halpern JL, Swan JC, Moss J, Parrillo JE, Masur H. Identification of antigens and antibodies specific for Pneumocystis carinii. J Immunol. 1988;140:2023–31.PubMedGoogle Scholar
  20. 20.
    Peglow SL, Smulian AG, Linke MJ, et al. Serologic responses to Pneumocystis carinii antigens in health and disease. J Infect Dis. 1990;161:296–306.PubMedGoogle Scholar
  21. 21.
    Pifer LL, Hughes WT, Stagno S, Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics. 1978;61:35–41.PubMedGoogle Scholar
  22. 22.
    Morris A, Lundgren JD, Masur H, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis. 2004;10:1713–20.PubMedGoogle Scholar
  23. 23.
    Spencer L, Ukwu M, Alexander T, et al. Epidemiology of Pneumocystis colonization in families. Clin Infect Dis. 2008;46:1237–40.PubMedGoogle Scholar
  24. 24.
    Walzer PD, Djawe K, Levin L, et al. Long-term serologic responses to the Pneumocystis jiroveci major surface glycoprotein in HIV-positive individuals with and without P. jiroveci infection. J Infect Dis. 2009;199:1335–44.PubMedGoogle Scholar
  25. 25.
    Davis JL, Welsh DA, Beard CB, et al. Pneumocystis colonisation is common among hospitalised HIV infected patients with non-Pneumocystis pneumonia. Thorax. 2008;63:329–34.PubMedGoogle Scholar
  26. 26.
    Bakeera-Kitaka S, Musoke P, Downing R, Tumwine JK. Pneumocystis carinii in children with severe pneumonia at Mulago Hospital, Uganda. Ann Trop Paediatr. 2004;24:227–35.PubMedGoogle Scholar
  27. 27.
    Fisk DT, Meshnick S, Kazanjian PH. Pneumocystis carinii pneumonia in patients in the developing world who have acquired immunodeficiency syndrome. Clin Infect Dis. 2003;36:70–8.PubMedGoogle Scholar
  28. 28.
    Tudor-Williams G. HIV infection in children in developing countries. Trans R Soc Trop Med Hyg. 2000;94:3–4.PubMedGoogle Scholar
  29. 29.
    Worodria W, Okot-Nwang M, Yoo SD, Aisu T. Causes of lower respiratory infection in HIV-infected Ugandan adults who are sputum AFB smear-negative. Int J Tuberc Lung Dis. 2003;7:117–23.PubMedGoogle Scholar
  30. 30.
    Hughes WT. Natural mode of acquisition for de novo infection with Pneumocystis carinii. J Infect Dis. 1982;145:842–8.PubMedGoogle Scholar
  31. 31.
    Beard CB, Fox MR, Lawrence GG, et al. Genetic differences in Pneumocystis isolates recovered from immunocompetent infants and from adults with AIDS: epidemiological implications. J Infect Dis. 2005;192:1815–8.PubMedGoogle Scholar
  32. 32.
    Huang L, Beard CB, Creasman J, et al. Sulfa or sulfone prophylaxis and geographic region predict mutations in the Pneumocystis carinii dihydropteroate synthase gene. J Infect Dis. 2000;182:1192–8.PubMedGoogle Scholar
  33. 33.
    Kazanjian P, Armstrong W, Hossler PA, et al. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J Infect Dis. 2000;182:551–7.PubMedGoogle Scholar
  34. 34.
    Kovacs JA, Masur H. Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA. 2009;301:2578–85.PubMedGoogle Scholar
  35. 35.
    Ripamonti C, Orenstein A, Kutty G, et al. Restriction fragment length polymorphism typing demonstrates substantial diversity among Pneumocystis jiroveci isolates. J Infect Dis. 2009;200:1616–22.PubMedGoogle Scholar
  36. 36.
    Helweg-Larsen J, Tsolaki AG, Miller RF, Lundgren B, Wakefield AE. Clusters of Pneumocystis carinii pneumonia: analysis of person-to-person transmission by genotyping. Q J Med. 1998;91:813–20.Google Scholar
  37. 37.
    Keely SP, Stringer JR. Sequences of Pneumocystis carinii f. sp. hominis strains associated with recurrent pneumonia vary at multiple loci. J Clin Microbiol. 1997;35:2745–7.PubMedGoogle Scholar
  38. 38.
    Keely SP, Stringer JR, Baughman RP, Linke MJ, Walzer PD, Smulian AG. Genetic variation among Pneumocystis carinii hominis isolates in recurrent pneumocystosis. J Infect Dis. 1995;172:595–8.PubMedGoogle Scholar
  39. 39.
    Rabodonirina M, Vanhems P, Couray-Targe S, et al. Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV-infected patients. Emerg Infect Dis. 2004;10:1766–73.PubMedGoogle Scholar
  40. 40.
    Vargas SL, Ponce CA, Galvez P, et al. Pneumocystis is not a direct cause of sudden infant death syndrome. Pediatr Infect Dis J. 2007;26:81–3.PubMedGoogle Scholar
  41. 41.
    Vargas SL, Ponce CA, Hughes WT, et al. Association of primary Pneumocystis carinii infection and sudden infant death syndrome. Clin Infect Dis. 1999;29:1489–93.PubMedGoogle Scholar
  42. 42.
    Morris A, Sciurba FC, Lebedeva IP, et al. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med. 2004;170:408–13.PubMedGoogle Scholar
  43. 43.
    Morris A, Netravali M, Kling HM, et al. Relationship of Pneumocystis antibody response to severity of chronic obstructive pulmonary disease. Clin Infect Dis. 2008;47:e64–8.PubMedGoogle Scholar
  44. 44.
    Browne MJ, Hubbard SM, Longo DL, et al. Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy. Ann Intern Med. 1986;104:338–44.PubMedGoogle Scholar
  45. 45.
    Byrd JC, Hargis JB, Kester KE, Hospenthal DR, Knutson SW, Diehl LF. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol. 1995;49:135–42.PubMedGoogle Scholar
  46. 46.
    Hughes WT, Feldman S, Aur RJ, Verzosa MS, Hustu HO, Simone JV. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer. 1975;36:2004–9.PubMedGoogle Scholar
  47. 47.
    Kolstad A, Holte H, Fossa A, Lauritzsen GF, Gaustad P, Torfoss D. Pneumocystis jiroveci pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica. 2007;92:139–40.PubMedGoogle Scholar
  48. 48.
    Komano Y, Harigai M, Koike R, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009;61:305–12.PubMedGoogle Scholar
  49. 49.
    Peters SG, Prakash UB. Pneumocystis carinii pneumonia. Review of 53 cases. Am J Med. 1987;82:73–8.PubMedGoogle Scholar
  50. 50.
    Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA. 1992;267:832–7.PubMedGoogle Scholar
  51. 51.
    Sugimoto H, Uchida H, Akiyama N, et al. Improved survival of renal allograft recipients with Pneumocystis carinii pneumonia by early diagnosis and treatment. Transplant Proc. 1992;24:1556–8.PubMedGoogle Scholar
  52. 52.
    Tuan IZ, Dennison D, Weisdorf DJ. Pneumocystis carinii pneumonitis following bone marrow transplantation. Bone Marrow Transplant. 1992;10:267–72.PubMedGoogle Scholar
  53. 53.
    Sowden E, Carmichael AJ. Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention. BMC Infect Dis. 2004;4:42.PubMedGoogle Scholar
  54. 54.
    Kadoya A, Okada J, Iikuni Y, Kondo H. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol. 1996;23:1186–8.PubMedGoogle Scholar
  55. 55.
    Sepkowitz KA. Pneumocystis carinii pneumonia among patients with neoplastic disease. Semin Respir Infect. 1992;7:114–21.PubMedGoogle Scholar
  56. 56.
    Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143–238.PubMedGoogle Scholar
  57. 57.
    Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2006;12:138–51.PubMedGoogle Scholar
  58. 58.
    Roths JB, Sidman CL. Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient scid mice. Infect Immun. 1993;61:1641–9.PubMedGoogle Scholar
  59. 59.
    Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71:5–13.PubMedGoogle Scholar
  60. 60.
    Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med. 1990;323:1451–7.PubMedGoogle Scholar
  61. 61.
    Masur H, Ognibene FP, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med. 1989;111:223–31.PubMedGoogle Scholar
  62. 62.
    Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med. 1990;322:161–5.PubMedGoogle Scholar
  63. 63.
    Chu SY, Hanson DL, Ciesielski C, Ward JW. Prophylaxis against Pneumocystis carinii pneumonia at higher CD4+ T-cell counts. JAMA. 1995;273:848.PubMedGoogle Scholar
  64. 64.
    Dworkin MS, Hanson DL, Navin TR. Survival of patients with AIDS, after diagnosis of Pneumocystis carinii pneumonia, in the United States. J Infect Dis. 2001;183:1409–12.PubMedGoogle Scholar
  65. 65.
    Dworkin MS, Hanson DL, Kaplan JE, Jones JL, Ward JW. Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4+ T lymphocyte counts above prophylaxis thresholds. J Infect Dis. 2000;182:611–5.PubMedGoogle Scholar
  66. 66.
    Lyles RH, Munoz A, Yamashita TE, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis. 2000;181:872–80.PubMedGoogle Scholar
  67. 67.
    Miller V, Mocroft A, Reiss P, et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med. 1999;130:570–7.PubMedGoogle Scholar
  68. 68.
    Mansharamani NG, Balachandran D, Vernovsky I, Garland R, Koziel H. Peripheral blood CD4  +  T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest. 2000;118:712–20.PubMedGoogle Scholar
  69. 69.
    Engelberg LA, Lerner CW, Tapper ML. Clinical features of Pneumocystis pneumonia in the acquired immune deficiency syndrome. Am Rev Respir Dis. 1984;130:689–94.PubMedGoogle Scholar
  70. 70.
    Walzer PD, Perl DP, Krogstad DJ, Rawson PG, Schultz MG. Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features. Ann Intern Med. 1974;80:83–93.PubMedGoogle Scholar
  71. 71.
    Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984;100:663–71.PubMedGoogle Scholar
  72. 72.
    Brenner M, Ognibene FP, Lack EE, et al. Prognostic factors and life expectancy of patients with acquired immunodeficiency syndrome and Pneumocystis carinii pneumonia. Am Rev Respir Dis. 1987;136:1199–206.PubMedGoogle Scholar
  73. 73.
    DeLorenzo LJ, Huang CT, Maguire GP, Stone DJ. Roentgenographic patterns of Pneumocystis carinii pneumonia in 104 patients with AIDS. Chest. 1987;91:323–7.PubMedGoogle Scholar
  74. 74.
    Gruden JF, Huang L, Turner J, et al. High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings. AJR. 1997;169:967–75.PubMedGoogle Scholar
  75. 75.
    Metersky ML, Colt HG, Olson LK, Shanks TG. AIDS-related spontaneous pneumothorax. Risk factors and treatment. Chest. 1995;108:946–51.PubMedGoogle Scholar
  76. 76.
    Sepkowitz KA, Telzak EE, Gold JW, et al. Pneumothorax in AIDS. Ann Intern Med. 1991;114:455–9.PubMedGoogle Scholar
  77. 77.
    Raviglione MC. Extrapulmonary pneumocystosis: the first 50 cases. Rev Infect Dis. 1990;12:1127–38.PubMedGoogle Scholar
  78. 78.
    Telzak EE, Cote RJ, Gold JW, Campbell SW, Armstrong D. Extrapulmonary Pneumocystis carinii infections. Rev Infect Dis. 1990;12:380–6.PubMedGoogle Scholar
  79. 79.
    Baughman R. Current methods in diagnosis. In: Walzer P, editor. Pneumocystis carinii pneumonia. New York: Marcel Dekker; 1994.Google Scholar
  80. 80.
    Meduri GU, Stover DE, Greeno RA, Nash T, Zaman MB. Bilateral bronchoalveolar lavage in the diagnosis of opportunistic pulmonary infections. Chest. 1991;100:1272–6.PubMedGoogle Scholar
  81. 81.
    Bigby TD, Margolskee D, Curtis JL, et al. The usefulness of induced sputum in the diagnosis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. Am Rev Respir Dis. 1986;133:515–8.PubMedGoogle Scholar
  82. 82.
    Kovacs JA, Halpern JL, Lundgren B, Swan JC, Parrillo JE, Masur H. Monoclonal antibodies to Pneumocystis carinii: identification of specific antigens and characterization of antigenic differences between rat and human isolates. J Infect Dis. 1989;159:60–70.PubMedGoogle Scholar
  83. 83.
    Kovacs JA, Ng VL, Masur H, et al. Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. N Engl J Med. 1988;318:589–93.PubMedGoogle Scholar
  84. 84.
    Ng VL, Virani NA, Chaisson RE, et al. Rapid detection of Pneumocystis carinii using a direct fluorescent monoclonal antibody stain. J Clin Microbiol. 1990;28:2228–33.PubMedGoogle Scholar
  85. 85.
    Pitchenik AE, Ganjei P, Torres A, Evans DA, Rubin E, Baier H. Sputum examination for the diagnosis of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Am Rev Respir Dis. 1986;133:226–9.PubMedGoogle Scholar
  86. 86.
    Kirsch CM, Jensen WA, Kagawa FT, Azzi RL. Analysis of induced sputum for the diagnosis of recurrent Pneumocystis carinii pneumonia. Chest. 1992;102:1152–4.PubMedGoogle Scholar
  87. 87.
    Gill VJ, Evans G, Stock F, Parrillo JE, Masur H, Kovacs JA. Detection of Pneumocystis carinii by fluorescent-antibody stain using a combination of three monoclonal antibodies. J Clin Microbiol. 1987;25:1837–40.PubMedGoogle Scholar
  88. 88.
    Huang SN, Fischer SH, O’Shaughnessy E, Gill VJ, Masur H, Kovacs JA. Development of a PCR assay for diagnosis of Pneumocystis carinii pneumonia based on amplification of the multicopy major surface glycoprotein gene family. Diagn Microbiol Infect Dis. 1999;35:27–32.PubMedGoogle Scholar
  89. 89.
    Wakefield AE, Pixley FJ, Banerji S, et al. Amplification of mitochondrial ribosomal RNA sequences from Pneumocystis carinii DNA of rat and human origin. Mol Biochem Parasitol. 1990;43:69–76.PubMedGoogle Scholar
  90. 90.
    Lipschik GY, Gill VJ, Lundgren JD, et al. Improved diagnosis of Pneumocystis carinii infection by polymerase chain reaction on induced sputum and blood. Lancet. 1992;340:203–6.PubMedGoogle Scholar
  91. 91.
    Lu JJ, Chen CH, Bartlett MS, Smith JW, Lee CH. Comparison of six different PCR methods for detection of Pneumocystis carinii. J Clin Microbiol. 1995;33:2785–8.PubMedGoogle Scholar
  92. 92.
    Gupta R, Mirdha BR, Guleria R, et al. Diagnostic significance of nested polymerase chain reaction for sensitive detection of Pneumocystis jiroveci in respiratory clinical specimens. Diagn Microbiol Infect Dis. 2009;64:381–8.PubMedGoogle Scholar
  93. 93.
    Helweg-Larsen J, Jensen JS, Benfield T, Svendsen UG, Lundgren JD, Lundgren B. Diagnostic use of PCR for detection of Pneumocystis carinii in oral wash samples. J Clin Microbiol. 1998;36:2068–72.PubMedGoogle Scholar
  94. 94.
    Larsen HH, Masur H, Kovacs JA, et al. Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia. J Clin Microbiol. 2002;40:490–4.PubMedGoogle Scholar
  95. 95.
    Fischer S, Gill VJ, Kovacs J, et al. The use of oral washes to diagnose Pneumocystis carinii pneumonia: a blinded prospective study using a polymerase chain reaction-based detection system. J Infect Dis. 2001;184:1485–8.PubMedGoogle Scholar
  96. 96.
    Bishop LR, Kovacs JA. Quantitation of anti-Pneumocystis jiroveci antibodies in healthy persons and immunocompromised patients. J Infect Dis. 2003;187:1844–8.PubMedGoogle Scholar
  97. 97.
    Daly KR, Huang L, Morris A, et al. Antibody response to Pneumocystis jiroveci major surface glycoprotein. Emerg Infect Dis. 2006;12:1231–7.PubMedGoogle Scholar
  98. 98.
    Skelly M, Hoffman J, Fabbri M, Holzman RS, Clarkson Jr AB, Merali S. S-adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia. Lancet. 2003;361:1267–8.PubMedGoogle Scholar
  99. 99.
    Wang P, Huang L, Davis JL, et al. A hydrophilic-interaction chromatography tandem mass spectrometry method for quantitation of serum S-adenosylmethionine in patients infected with human immunodeficiency virus. Clin Chim Acta. 2008;396:86–8.PubMedGoogle Scholar
  100. 100.
    Shimizu Y, Sunaga N, Dobashi K, et al. Serum markers in interstitial pneumonia with and without Pneumocystis jiroveci colonization: a prospective study. BMC Infect Dis. 2009;9:47.PubMedGoogle Scholar
  101. 101.
    Tasaka S, Hasegawa N, Kobayashi S, et al. Serum indicators for the diagnosis of Pneumocystis pneumonia. Chest. 2007;131:1173–80.PubMedGoogle Scholar
  102. 102.
    Watanabe T, Yasuoka A, Tanuma J, et al. Serum (1–  >  3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis. 2009;49:1128–31.PubMedGoogle Scholar
  103. 103.
    Del Bono V, Mularoni A, Furfaro E, et al. Clinical evaluation of a (1, 3)-beta-D-glucan assay for presumptive diagnosis of Pneumocystis jiroveci pneumonia in immunocompromised patients. Clin Vaccine Immunol. 2009;16:1524–6.PubMedGoogle Scholar
  104. 104.
    Desmet S, Van Wijngaerden E, Maertens J, et al. Serum (1-3)-{beta}-D-glucan as a diagnostic tool for Pneumocystis jiroveci pneumonia in patients with HIV infection or hematological malignancy. J Clin Microbiol. 2009;47:3871–4.PubMedGoogle Scholar
  105. 105.
    Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med. 1988;109:280–7.PubMedGoogle Scholar
  106. 106.
    Ruf B, Rohde I, Pohle HD. Efficacy of clindamycin/primaquine versus trimethoprim/sulfamethoxazole in primary treatment of Pneumocystis carinii pneumonia. Eur J Clin Microbiol Infect Dis. 1991;10:207–10.PubMedGoogle Scholar
  107. 107.
    Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med. 1996;124:792–802.PubMedGoogle Scholar
  108. 108.
    Toma E. Clindamycin/primaquine for treatment of Pneumocystis carinii pneumonia in AIDS. Eur J Clin Microbiol Infect Dis. 1991;10:210–3.PubMedGoogle Scholar
  109. 109.
    Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58:1–207. quiz CE1-4.Google Scholar
  110. 110.
    Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med. 1992;327:1842–8.PubMedGoogle Scholar
  111. 111.
    Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. N Engl J Med. 1992;327:1836–41.PubMedGoogle Scholar
  112. 112.
    Conte Jr JE, Chernoff D, Feigal Jr DW, Joseph P, McDonald C, Golden JA. Intravenous or inhaled pentamidine for treating Pneumocystis carinii pneumonia in AIDS. A randomized trial. Ann Intern Med. 1990;113:203–9.PubMedGoogle Scholar
  113. 113.
    Conte Jr JE, Hollander H, Golden JA. Inhaled or reduced-dose intravenous pentamidine for Pneumocystis carinii pneumonia. A pilot study. Ann Intern Med. 1987;107:495–8.PubMedGoogle Scholar
  114. 114.
    Leoung GS, Feigal Jr DW, Montgomery AB, et al. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial. N Engl J Med. 1990;323:769–75.PubMedGoogle Scholar
  115. 115.
    Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med. 1990;323:776–82.PubMedGoogle Scholar
  116. 116.
    Hughes W, Leoung G, Kramer F, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993;328:1521–7.PubMedGoogle Scholar
  117. 117.
    Mills J, Leoung G, Medina I, Hopewell PC, Hughes WT, Wofsy C. Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Antimicrob Agents Chemother. 1988;32:1057–60.PubMedGoogle Scholar
  118. 118.
    Safrin S, Sattler FR, Lee BL, et al. Dapsone as a single agent is suboptimal therapy for Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr. 1991;4:244–9.PubMedGoogle Scholar
  119. 119.
    Leoung GS, Mills J, Hopewell PC, Hughes W, Wofsy C. Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med. 1986;105:45–8.PubMedGoogle Scholar
  120. 120.
    Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med. 1995;332:693–9.PubMedGoogle Scholar
  121. 121.
    Noskin GA, Murphy RL, Black JR, Phair JP. Salvage therapy with clindamycin/primaquine for Pneumocystis carinii pneumonia. Clin Infect Dis. 1992;14:183–8.PubMedGoogle Scholar
  122. 122.
    Dohn MN, Weinberg WG, Torres RA, et al. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group. Ann Intern Med. 1994;121:174–80.PubMedGoogle Scholar
  123. 123.
    Catterall JR, Potasman I, Remington JS. Pneumocystis carinii pneumonia in the patient with AIDS. Chest. 1985;88:758–62.PubMedGoogle Scholar
  124. 124.
    Annaloro C, Della Volpe A, Usardi P, Lambertenghi Deliliers G. Caspofungin treatment of Pneumocystis pneumonia during conditioning for bone marrow transplantation. Eur J Clin Microbiol Infect Dis. 2006;25:52–4.PubMedGoogle Scholar
  125. 125.
    Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis. 2003;36:1445–57.PubMedGoogle Scholar
  126. 126.
    Kamboj M, Weinstock D, Sepkowitz KA. Progression of Pneumocystis jiroveci pneumonia in patients receiving echinocandin therapy. Clin Infect Dis. 2006;43:e92–4.PubMedGoogle Scholar
  127. 127.
    Utili R, Durante-Mangoni E, Basilico C, Mattei A, Ragone E, Grossi P. Efficacy of caspofungin addition to trimethoprim-sulfamethoxazole treatment for severe Pneumocystis pneumonia in solid organ transplant recipients. Transplantation. 2007;84:685–8.PubMedGoogle Scholar
  128. 128.
    Gagnon S, Boota AM, Fischl MA, Baier H, Kirksey OW, La Voie L. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. N Engl J Med. 1990;323:1444–50.PubMedGoogle Scholar
  129. 129.
    Briel M, Bucher HC, Boscacci R, Furrer H. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. Cochrane Database Syst Rev. 2006;3:CD006150.PubMedGoogle Scholar
  130. 130.
    Delclaux C, Zahar JR, Amraoui G, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients. Clin Infect Dis. 1999;29:670–2.PubMedGoogle Scholar
  131. 131.
    Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998;113:1215–24.PubMedGoogle Scholar
  132. 132.
    Montaner JS, Lawson LM, Gervais A, et al. Aerosol pentamidine for secondary prophylaxis of AIDS-related Pneumocystis carinii pneumonia. A randomized, placebo-controlled study. Ann Intern Med. 1991;114:948–53.PubMedGoogle Scholar
  133. 133.
    Dohn MN, Baughman RP, Vigdorth EM, Frame DL. Equal survival rates for first, second, and third episodes of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1992;152:2465–70.PubMedGoogle Scholar
  134. 134.
    Kales CP, Murren JR, Torres RA, Crocco JA. Early predictors of in-hospital mortality for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Arch Intern Med. 1987;147:1413–7.PubMedGoogle Scholar
  135. 135.
    Shelhamer JH, Ognibene FP, Macher AM, et al. Persistence of Pneumocystis carinii in lung tissue of acquired immunodeficiency syndrome patients treated for Pneumocystis pneumonia. Am Rev Respir Dis. 1984;130:1161–5.PubMedGoogle Scholar
  136. 136.
    Radhi S, Alexander T, Ukwu M, Saleh S, Morris A. Outcome of HIV-associated Pneumocystis pneumonia in hospitalized patients from 2000 through 2003. BMC Infect Dis. 2008;8:118.PubMedGoogle Scholar
  137. 137.
    Morris A. Is there anything new in Pneumocystis jirovecii pneumonia? Changes in P. jiroveci pneumonia over the course of the AIDS epidemic. Clin Infect Dis. 2008;46:634–6.PubMedGoogle Scholar
  138. 138.
    Powell K, Davis JL, Morris AM, Chi A, Bensley MR, Huang L. Survival for patients With HIV admitted to the ICU continues to improve in the current era of combination antiretroviral therapy. Chest. 2009;135:11–7.PubMedGoogle Scholar
  139. 139.
    Stover DE, Zaman MB, Hajdu SI, Lange M, Gold J, Armstrong D. Bronchoalveolar lavage in the diagnosis of diffuse pulmonary infiltrates in the immunosuppressed host. Ann Intern Med. 1984;101:1–7.PubMedGoogle Scholar
  140. 140.
    Barry SM, Lipman MC, Deery AR, Johnson MA, Janossy G. Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV-infected subjects. HIV Med. 2002;3:207–11.PubMedGoogle Scholar
  141. 141.
    Dean GL, Williams DI, Churchill DR, Fisher MJ. Transient clinical deterioration in HIV patients with Pneumocystis carinii pneumonia after starting highly active antiretroviral therapy: another case of immune restoration inflammatory syndrome. Am J Respir Crit Care Med. 2002;165(Dean GL, Williams DI, Churchill DR, Fisher MJ):1670. author reply.PubMedGoogle Scholar
  142. 142.
    Koval CE, Gigliotti F, Nevins D, Demeter LM. Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection. Clin Infect Dis. 2002;35:491–3.PubMedGoogle Scholar
  143. 143.
    Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis. 2006;42:418–27.PubMedGoogle Scholar
  144. 144.
    Wislez M, Bergot E, Antoine M, et al. Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia. Am J Respir Crit Care Med. 2001;164:847–51.PubMedGoogle Scholar
  145. 145.
    Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE. 2009;4:e5575.PubMedGoogle Scholar
  146. 146.
    Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis. 2004;38:1159–66.PubMedGoogle Scholar
  147. 147.
    Gryzan S, Paradis IL, Zeevi A, et al. Unexpectedly high incidence of Pneumocystis carinii infection after lung-heart transplantation. Implications for lung defense and allograft survival. Am Rev Respir Dis. 1988;137:1268–74.PubMedGoogle Scholar
  148. 148.
    Henson JW, Jalaj JK, Walker RW, Stover DE, Fels AO. Pneumocystis carinii pneumonia in patients with primary brain tumors. Arch Neurol. 1991;48:406–9.PubMedGoogle Scholar
  149. 149.
    Masur H. Prevention and treatment of Pneumocystis pneumonia. N Engl J Med. 1992;327:1853–60.PubMedGoogle Scholar
  150. 150.
    Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev. 2004;17:770–82.PubMedGoogle Scholar
  151. 151.
    Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA. 1988;259:1185–9.PubMedGoogle Scholar
  152. 152.
    Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant. 2009;44:453–5.PubMedGoogle Scholar
  153. 153.
    Winston DJ. Prophylaxis and treatment of infection in the bone marrow transplant recipient. Curr Clin Topics Infect Dis. 1993;13:293–321.Google Scholar
  154. 154.
    Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000;49:1–125, CE1-7.Google Scholar
  155. 155.
    De Castro N, Neuville S, Sarfati C, et al. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant. 2005;36:879–83.PubMedGoogle Scholar
  156. 156.
    Kovacs JA, Masur H. Prophylaxis for Pneumocystis carinii pneumonia in patients infected with human immunodeficiency virus. Clin Infect Dis. 1992;14:1005–9.PubMedGoogle Scholar
  157. 157.
    Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep. 2009;58:1–166.PubMedGoogle Scholar
  158. 158.
    Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med. 1999;340:1301–6.PubMedGoogle Scholar
  159. 159.
    Furrer H, Opravil M, Rossi M, et al. Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study. AIDS. 2001;15:501–7.PubMedGoogle Scholar
  160. 160.
    Green H, Hay P, Dunn DT, McCormack S. A prospective multicentre study of discontinuing prophylaxis for opportunistic infections after effective antiretroviral therapy. HIV Med. 2004;5:278–83.PubMedGoogle Scholar
  161. 161.
    Kirk O, Lundgren JD, Pedersen C, Nielsen H, Gerstoft J. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? AIDS. 1999;13:1647–51.PubMedGoogle Scholar
  162. 162.
    Ledergerber B, Mocroft A, Reiss P, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med. 2001;344:168–74.PubMedGoogle Scholar
  163. 163.
    de Quiros JC Lopez Bernaldo, Miro JM, Pena JM, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med. 2001;344:159–67.Google Scholar
  164. 164.
    D’Egidio GE, Kravcik S, Cooper CL, Cameron DW, Fergusson DA, Angel JB. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count  <  200 cells/microl when viral replication is suppressed. AIDS. 2007;21:1711–5.PubMedGoogle Scholar
  165. 165.
    Girard PM, Landman R, Gaudebout C, et al. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group. N Engl J Med. 1993;328:1514–20.PubMedGoogle Scholar
  166. 166.
    Hardy WD, Northfelt DW, Drake TA. Fatal, disseminated pneumocystosis in a patient with acquired immunodeficiency syndrome receiving prophylactic aerosolized pentamidine. Am J Med. 1989;87:329–31.PubMedGoogle Scholar
  167. 167.
    Ioannidis JP, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med. 1996;156:177–88.PubMedGoogle Scholar
  168. 168.
    Podzamczer D, Salazar A, Jimenez J, et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med. 1995;122:755–61.PubMedGoogle Scholar
  169. 169.
    Saah AJ, Hoover DR, Peng Y, et al. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study. JAMA. 1995;273:1197–202.PubMedGoogle Scholar
  170. 170.
    El-Sadr WM, Luskin-Hawk R, Yurik TM, et al. A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Clin Infect Dis. 1999;29:775–83.PubMedGoogle Scholar
  171. 171.
    Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1987;316:1627–32.PubMedGoogle Scholar
  172. 172.
    Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med. 1992;117:106–11.PubMedGoogle Scholar
  173. 173.
    Conte Jr JE, Upton RA, Phelps RT, Wofsy CB, Zurlinden E, Lin ET. Use of a specific and sensitive assay to determine pentamidine pharmacokinetics in patients with AIDS. J Infect Dis. 1986;154:923–9.PubMedGoogle Scholar
  174. 174.
    Murphy RL, Lavelle JP, Allan JD, et al. Aerosol pentamidine prophylaxis following Pneumocystis carinii pneumonia in AIDS patients: results of a blinded dose-comparison study using an ultrasonic nebulizer. Am J Med. 1991;90:418–26.PubMedGoogle Scholar
  175. 175.
    Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. The National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. N Engl J Med. 1990;323:1500–4.Google Scholar
  176. 176.
    Blumberg HM, Watkins DL, Berschling JD, et al. Preventing the nosocomial transmission of tuberculosis. Ann Intern Med. 1995;122:658–63.PubMedGoogle Scholar
  177. 177.
    Holtzer CD, Flaherty Jr JF, Coleman RL. Cross-reactivity in HIV-infected patients switched from trimethoprim-sulfamethoxazole to dapsone. Pharmacotherapy. 1998;18:831–5.PubMedGoogle Scholar
  178. 178.
    Sangiolo D, Storer B, Nash R, et al. Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study. Biol Blood Marrow Transplant. 2005;11:521–9.PubMedGoogle Scholar
  179. 179.
    Lavelle J, Falloon J, Morgan A, et al. Weekly dapsone and dapson/pyrimethamine for Pneumocystis pneumonia prophylaxis. In: VII International Conference on AIDS 1991;7:233. Florence; 1991.Google Scholar
  180. 180.
    Opravil M, Hirschel B, Lazzarin A, et al. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis. 1995;20:531–41.PubMedGoogle Scholar
  181. 181.
    Chan C, Montaner J, Lefebvre EA, et al. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis. 1999;180:369–76.PubMedGoogle Scholar
  182. 182.
    El-Sadr WM, Murphy RL, Yurik TM, et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med. 1998;339:1889–95.PubMedGoogle Scholar
  183. 183.
    Kazanjian P, Locke AB, Hossler PA, et al. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS. 1998;12:873–8.PubMedGoogle Scholar
  184. 184.
    Mei Q, Gurunathan S, Masur H, Kovacs JA. Failure of co-trimoxazole in Pneumocystis carinii infection and mutations in dihydropteroate synthase gene. Lancet. 1998;351:1631–2.PubMedGoogle Scholar
  185. 185.
    Crothers K, Beard CB, Turner J, et al. Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jiroveci dihydropteroate synthase gene mutations. AIDS. 2005;19:801–5.PubMedGoogle Scholar
  186. 186.
    Helweg-Larsen J, Benfield TL, Eugen-Olsen J, Lundgren JD, Lundgren B. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet. 1999;354:1347–51.PubMedGoogle Scholar
  187. 187.
    Navin TR, Beard CB, Huang L, et al. Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P. carinii pneumonia in patients with HIV-1: a prospective study. Lancet. 2001;358:545–9.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Critical Care MedicineNational Institutes of HealthBethesdaUSA

Personalised recommendations